Targeting the complement activation fragment C5a to improve the outcome from spinal cord injury

靶向补体激活片段 C5a 以改善脊髓损伤的结果

• 批准号: nhmrc : 1060538
• 负责人: A/Pr Marc Ruitenberg
• 金额: $ 27.13万
• 依托单位: The University of Queensland
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2014
• 资助国家: 澳大利亚
• 起止时间: 2014-01-01 至 2017-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/targeting-complement-activation-cord-injury/454837
• 关键词: Targeting; complement; activation; fragment; C5a

This project will focus on the development of a new drug that is designed to attenuate the harmful inflammatory response that follows from spinal cord injury (SCI). The experiments will determine if the therapeutic targeting of an immune receptor molecule, called C5aR, can protect compromised neural tissues after injury against harmful inflammation and degeneration whilst also explore the mechanism behind the therapeutic effect.

该项目将重点开发一种新药，旨在减轻脊髓损伤（SCI）后的有害炎症反应。实验将确定一种名为C5aR的免疫受体分子的治疗靶向是否可以保护受损的神经组织免受有害炎症和变性的伤害，同时也探索治疗效果背后的机制。